William T Hu

List of Publications by Year
in descending order

101 papers	5,820 citations	70961 41 h-index	79541 73 g-index
112 all docs	112 docs citations	112 times ranked	9681 citing authors

#	Article	IF	Citations
1	Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nature Immunology, 2020, 21, 1506-1516.	7.0	563
2	Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. Nature Medicine, 2014, 20, 1254-1262.	15.2	367
3	The future of bloodâ€based biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 115-131.	0.4	250
4	Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology, 2008, 70, 1850-1857.	1.5	220
5	Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology, 2012, 79, 897-905.	1.5	208
6	Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72 -associated amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	5.8	179
7	Novel CSF biomarkers for Alzheimerâ€™s disease and mild cognitive impairment. Acta Neuropathologica, 2010, 119, 669-678.	3.9	164
8	CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathologica, 2012, 124, 23-35.	3.9	161
9	Distinct cerebral perfusion patterns in FTLD and AD. Neurology, 2010, 75, 881-888.	1.5	153
10	Encephalopathy and Encephalitis Associated with Cerebrospinal Fluid Cytokine Alterations and Coronavirus Disease, Atlanta, Georgia, USA, 2020. Emerging Infectious Diseases, 2020, 26, 2016-2021.	2.0	145
11	Cognitive Impairment and Celiac Disease. Archives of Neurology, 2006, 63, 1440.	4.9	143
12	Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology, 2008, 70, 25-34.	1.5	143
13	Race modifies the relationship between cognition and Alzheimerâ€™s disease cerebrospinal fluid biomarkers. Alzheimer's Research and Therapy, 2017, 9, 88.	3.0	139
14	Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Annals of Neurology, 2011, 69, 655-663.	2.8	126
15	Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathologica, 2008, 116, 215-220.	3.9	124
16	Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease. Alzheimer's Research and Therapy, 2013, 5, 21.	3.0	124
17	Alzheimerâ€™s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	3.7	109
18	Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration. Archives of Neurology, 2011, 68, 488.	4.9	108

#	Article	IF	Citations
19	Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome. Movement Disorders, 2009, 24, 1375-1379.	2.2	105
20	Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathologica, 2011, 121, 373-380.	3.9	102
21	Reduced CSF p-Tau ₁₈₁ to Tau ratio is a biomarker for FTLD-TDP. Neurology, 2013, 81, 1945-1952.	1.5	100
22	Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia. Neurology, 2010, 75, 595-602.	1.5	98
23	CSF Cytokines in Aging, Multiple Sclerosis, and Dementia. Frontiers in Immunology, 2019, 10, 480.	2.2	91
24	Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology, 2010, 75, 2079-2086.	1.5	89
25	Phosphorylated neurofilament heavy chain: A biomarker of survival for <scp>C9ORF</scp>72â€associated amyotrophic lateral sclerosis. Annals of Neurology, 2017, 82, 139-146.	2.8	88
26	Survival Profiles of Patients With Frontotemporal Dementia and Motor Neuron Disease. Archives of Neurology, 2009, 66, 1359-64.	4.9	83
27	Trehalose upregulates progranulin expression in human and mouse models of GRN haploinsufficiency: a novel therapeutic lead to treat frontotemporal dementia. Molecular Neurodegeneration, 2016, 11, 46.	4.4	82
28	Biomarker discovery for Alzheimerâ€™s disease, frontotemporal lobar degeneration, and Parkinsonâ€™s disease. Acta Neuropathologica, 2010, 120, 385-399.	3.9	79
29	Phosphorylated Tau as a Candidate Biomarker for Amyotrophic Lateral Sclerosis. JAMA Neurology, 2014, 71, 442.	4.5	74
30	Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. Neurology, 2016, 87, 1024-1030.	1.5	74
31	Amyloid-beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation. Journal of Neurochemistry, 2004, 86, 470-478.	2.1	73
32	Anatomical differences between CBSâ€corticobasal degeneration and CBSâ€Alzheimer's disease. Movement Disorders, 2010, 25, 1246-1252.	2.2	71
33	Long-Term Follow-up after Treatment of Rabies by Induction of Coma. New England Journal of Medicine, 2007, 357, 945-946.	13.9	70
34	Behavior Mattersâ€”Cognitive Predictors of Survival in Amyotrophic Lateral Sclerosis. PLoS ONE, 2013, 8, e57584.	1.1	61
35	Herpes simplex virus blocks host transcription termination via the bimodal activities of ICP27. Nature Communications, 2020, 11, 293.	5.8	58
36	Association of plasma C-reactive protein levels with the diagnosis of Alzheimer's disease. Journal of the Neurological Sciences, 2013, 333, 9-12.	0.3	55

#	Article	IF	Citations
37	Low Plasma Leptin in Cognitively Impaired ADNI Subjects: Gender Differences and Diagnostic and Therapeutic Potential. Current Alzheimer Research, 2014, 11, 165-174.	0.7	54
38	Ornithine Transcarbamylase Deficiency Presenting as Encephalopathy During Adulthood Following Bariatric Surgery. Archives of Neurology, 2007, 64, 126.	4.9	49
39	Plasma biomarkers of depressive symptoms in older adults. Translational Psychiatry, 2012, 2, e65-e65.	2.4	48
40	The advantages of frontotemporal degeneration drug development (partÂ2Âof frontotemporal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62	0.4	48
41	LATE to the PART-y. Brain, 2019, 142, e47-e47.	3.7	44
42	Interleukin 9 alterations linked to alzheimer disease in african americans. Annals of Neurology, 2019, 86, 407-418.	2.8	42
43	Highâ€resolution metabolomic profiling of Alzheimerâ€™s disease in plasma. Annals of Clinical and Translational Neurology, 2020, 7, 36-45.	1.7	42
44	Biomarkers in frontotemporal lobar degenerationsâ€”Progress and challenges. Progress in Neurobiology, 2011, 95, 636-648.	2.8	36
45	Clinical Features of Pathologic Subtypes of Behavioral-Variant Frontotemporal Dementia. Archives of Neurology, 2007, 64, 1611.	4.9	35
46	Identifying amyloid pathologyâ€“related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 339-348.	1.2	35
47	CSF complement 3 and factor H are staging biomarkers in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2016, 4, 14.	2.4	35
48	CSF betaâ€amyloid 1â€“42 â€“ what are we measuring in Alzheimer's disease?. Annals of Clinical and Translational Neurology, 2015, 2, 131-139.	1.7	34
49	Research Lumbar Punctures among African Americans and Caucasians: Perception Predicts Experience. Frontiers in Aging Neuroscience, 2016, 8, 296.	1.7	33
50	Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2018, 10, 98.	3.0	25
51	Automation vs. Experience: Measuring Alzheimerâ€™s Beta-Amyloid 1â€“42 Peptide in the CSF. Frontiers in Aging Neuroscience, 2018, 10, 253.	1.7	25
52	Clinical Features and Survival of 3R and 4R Tauopathies Presenting as Behavioral Variant Frontotemporal Dementia. Alzheimer Disease and Associated Disorders, 2007, 21, S39-S43.	0.6	23
53	Perspective on the â€œAfrican American participation in Alzheimer disease research: Effective strategiesâ€• workshop, 2018. Alzheimer's and Dementia, 2020, 16, 1734-1744.	0.4	23
54	MRI correlates of alien leg-like phenomenon in corticobasal degeneration. Movement Disorders, 2005, 20, 870-873.	2.2	21

#	Article	IF	Citations
55	NMR metabolomics of cerebrospinal fluid differentiates inflammatory diseases of the central nervous system. PLoS Neglected Tropical Diseases, 2018, 12, e0007045.	1.3	21
56	Novel <scp>CSF</scp> biomarkers to discriminate <scp>FTLD</scp> and its pathological subtypes. Annals of Clinical and Translational Neurology, 2018, 5, 1163-1175.	1.7	20
57	TDP-43 and frontotemporal dementia. Current Neurology and Neuroscience Reports, 2009, 9, 353-358.	2.0	19
58	Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimerâ€™s disease. Nature Communications, 2021, 12, 4001.	5.8	19
59	A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimerâ€™s Disease Using Artificial Intelligence and Machine Learning. Journal of Alzheimer's Disease, 2020, 78, 1381-1392.	1.2	16
60	Race modifies default mode connectivity in Alzheimerâ€™s disease. Translational Neurodegeneration, 2020, 9, 8.	3.6	16
61	Childhood obesity among Head Start enrollees in southeastern Minnesota: prevalence and risk factors. Ethnicity and Disease, 2007, 17, 23-8.	1.0	16
62	Baseline Results: The Association Between Cardiovascular Risk and Preclinical Alzheimerâ€™s Disease Pathology (ASCEND) Study. Journal of Alzheimer's Disease, 2020, 75, 109-117.	1.2	15
63	Linked CSF reduction of phosphorylated tau and IL-8 in HIV associated neurocognitive disorder. Scientific Reports, 2019, 9, 8733.	1.6	14
64	From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers. International Review of Psychiatry, 2013, 25, 210-220.	1.4	13
65	Fear and Uncertainty Do Not Influence Reported Willingness to Undergo Lumbar Punctures in a U.S. Multi-Cultural Cohort. Frontiers in Aging Neuroscience, 2017, 9, 22.	1.7	11
66	Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 62, 1815-1826.	1.2	11
67	Sudden Coma Due to Acute Bilateral M1 Occlusion. Mayo Clinic Proceedings, 2007, 82, 1155.	1.4	10
68	Extrapyramidal reaction to ondansetron and propofol. Movement Disorders, 2009, 24, 312-313.	2.2	10
69	Knowledge and Attitudes in Alzheimerâ€™s Disease in a Cohort of Older African Americans and Caucasians. American Journal of Alzheimer's Disease and Other Dementias, 2016, 31, 361-367.	0.9	10
70	Natural History of â€œPureâ€•Primary Lateral Sclerosis. Neurology, 2021, 96, e2231-e2238.	1.5	9
71	Patients with Mild Cognitive Impairment May be Stratified by Advanced Diffusion Metrics and Neurocognitive Testing. Journal of Neuroimaging, 2019, 29, 79-84.	1.0	8
72	Cerebrospinal Fluid Hypocretin and Nightmares in Dementia Syndromes. Dementia and Geriatric Cognitive Disorders Extra, 2021, 11, 19-25.	0.6	6

#	Article	IF	Citations
73	Alzheimerâ€™s disease biomarkers: walk with deliberate haste, donâ€™t run blithely on?. Acta Neuropathologica, 2013, 126, 625-629.	3.9	5
74	Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology, 2013, 80, 690-691.	1.5	5
75	Cross-species metabolomic analysis of tau- and DDT-related toxicity. , 2022, 1, .		5
76	No doubts about dementia advocacy. Lancet Psychiatry,the, 2017, 4, 830.	3.7	3
77	Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies. Biomolecules, 2021, 11, 1484.	1.8	3
78	MRI findings of rapidly progressive ophthalmoplegia and blindness in mucormycosis. Neurology, 2006, 66, E40-E40.	1.5	2
79	Does limited EMG denervation in early primary lateral sclerosis predict amyotrophic lateral sclerosis?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 554-561.	1.1	2
80	Cerebral AÎ² deposition in an AÎ²-precursor protein-transgenic rhesus monkey. Aging Brain, 2022, 2, 100044.	0.7	2
81	[P4â€“471]: VALIDATING NONâ€AMYLOID, NONâ€TAU CSF BIOMARKERS FOR ALZHEIMER'S DISEASE IN THE PREâ€SYMPTOMATIC, MCI, AND DEMENTIA STAGES: A MULTIâ€CENTER STUDY. Alzheimer's and Dementia, 2017, 13, P1513.	0.4	1
82	0712 APOE4, But Not Desaturation Index, Is Associated with Dementia Severity In A Memory Clinic Population. Sleep, 2019, 42, A285-A286.	0.6	1
83	A pilot clinical trial of adapted tango to improve negative health impacts in middle aged Africanâ€American women caregivers of persons with Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e044865.	0.4	1
84	A Pilot Randomized Clinical Trial of Adapted Tango to Improve Cognition and Psychosocial Function in African American Women with Family History of Alzheimer's Disease (ACT trial). Cerebral Circulation - Cognition and Behavior, 2021, , 100018.	0.4	1
85	Reporting and social construction of race in Alzheimer's disease clinical trials. Alzheimer's and Dementia, 2022, 18, 865-866.	0.4	1
86	Racial differences in biomarkers of Alzheimerâ€™s disease and inflammation. Alzheimer's and Dementia, 2021, 17, .	0.4	1
87	75-Year-Old Man With Progressive Shortness of Breath on Exertion. Mayo Clinic Proceedings, 2005, 80, 1651-1654.	1.4	0
88	PATIENT MANAGEMENT PROBLEM. CONTINUUM Lifelong Learning in Neurology, 2010, 16, 153-164.	0.4	0
89	Neuroimaging of other dementing disorders. , 0, , 371-394.		0
90	P4â€“123: Resolving Conflicting CSF Biomarker Information in Alzheimerâ€²s Disease. Alzheimer's and Dementia, 2016, 12, P1061.	0.4	0

#	Article	IF	Citations
91	O1â€11â€06: Lower Prevalence of Abnormal CSF Alzheimerâ€™s Biomarkers Among African Americans than Caucasians with Normal Cognition or Cognitive Impairment. Alzheimer's and Dementia, 2016, 12, P204.	0.4	0
92	[P4â€“472]: WHAT IS DEMENTIA FRIENDLY? DEVELOPMENT AND VALIDATION OF A NOVEL TOOL TO MEASURE STIGMA ASSOCIATED WITH DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1514.	0.4	0
93	ICâ€Pâ€039: RACE MODIFIES FUNCTIONAL CONNECTIVITY OF THE DEFAULT MODE NETWORK IN AGING AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P40.	0.4	0
94	P2â€651: A CONSENSUS AROUND GLOBAL RESEARCH PRIORITIES FOR COMMUNITYâ€BASED CARE FROM A STRATEGIC CONVENING MODEL IN SALZBURG, AUSTRIA. Alzheimer's and Dementia, 2018, 14, P992.	0.4	0
95	O2â€02â€01: DIFFERENT CSF TOTAL AND PHOSPHORYLATED TAU, BUT NOT AÎ², IN OLDER AND YOUNGER AFRICAN AMERICANS AND WHITES. Alzheimer's and Dementia, 2019, 15, P535.	0.4	0
96	Race modifies putamen connectivity in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e043597.	0.4	0
97	Localization and protein levels of YKLâ€40 in postmortem brain of frontotemporal dementia and Alzheimerâ€™s disease cases. Alzheimer's and Dementia, 2020, 16, e044523.	0.4	0
98	Trust thyself: How older black and white adults consider Alzheimerâ€™s disease research participation. Alzheimer's and Dementia, 2020, 16, e044858.	0.4	0
99	CSF biomarkers for frontotemporal dementia and its pathological subtypes. Alzheimer's and Dementia, 2020, 16, e045851.	0.4	0
100	Caution on Plasma Cytokine Findings in 2019 Novel Coronavirus Cases. SSRN Electronic Journal, 2020, , 3555849.	0.4	0
101	Amyloid-beta alters trafficking of internalized acetylcholinesterase and dextran. International Journal of Physiology, Pathophysiology and Pharmacology, 2009, 1, 15-24.	0.8	0